LCS3 is an inhibitor of glutathione reductase (GR) and thioredoxin reductase (TrxR; IC50s = 3.3 and 3.8 µM, respectively).1 It decreases the glutathione (GSH) to oxidized GSH (GSSG) ratio in NCI H1650 and H23 lung adenocarcinoma cells in a concentration-dependent manner. LCS3 (3 µM) induces apoptosis in NCI H1650 and H23 cells but not non-transformed HPL1D lung epithelial cells. It is also active against M. tuberculosis (MIC = 0.098 µM).2
1.Johnson, F.D., Ferrarone, J., Liu, A., et al.Characterization of a small molecule inhibitor of disulfide reductases that induces oxidative stress and lethality in lung cancer cellsCell Rep.38(6)110343(2022) 2.Gallardo-Marcias, R., Kumar, P., Jaskowski, M., et al.Optimization of N-benzyl-5-nitrofuran-2-carboxamide as an antitubercular agentBioorg. Med. Chem. Lett.29(4)601-606(2019)